Aliskiren Reduces Body-weight Gain, Adiposity and Plasma Leptin During Diet-induced Obesity

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Aug 22

PMID 19694726

Citations 29

Authors

Paula Stucchi

Victoria Cano

Mariano Ruiz-Gayo

Maria S Fernandez-Alfonso

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Overfeeding increases adipose tissue mass and leptin production and up-regulates the renin-angiotensin system in adipose tissue in rodents. Here, we determined the effect of chronic treatment with the renin inhibitor, aliskiren, in a model of diet-induced obesity in mice, on: (i) body weight, adipose tissue weight and plasma leptin; (ii) food intake and caloric efficiency; and (iii) angiotensin II (Ang II) in adipose tissue.

Experimental Approach: Four-week-old C57BL/6J mice (n= 40) received aliskiren (50 mg.kg(-1).day(-1); 6 weeks) by means of a subcutaneous osmotic Alzet minipump. Animals were given either a low-fat (10% kcal from fat) or a high-fat diet (45% kcal from fat) during this period. Food-intake and body-weight variation were monitored during treatment.

Key Results: In addition to a decrease of plasma renin activity, aliskiren reduced body-weight gain, adipose pads and plasma leptin concentration, independent of the diet. In adipose tissue, local concentrations of Ang II were also reduced by aliskiren.

Conclusions And Implications: Aliskiren limited the gain of adiposity in young mice. This effect was not due to changes in food intake or caloric efficiency and might be related to a down-regulation of the local renin-angiotensin system in adipose tissue. These effects were accompanied by reduced plasma leptin levels. As Ang II favours differentiation of adipocytes, it is possible that the decreased adipose tissue was linked to changes in adipocyte size and number.

Citing Articles

Antisense oligonucleotides targeting hepatic angiotensinogen reduce atherosclerosis and liver steatosis in hypercholesterolemic mice.

Ye D, Wu C, Cai L, Howatt D, Liang C, Katsumata Y Glob Transl Med. 2023; 2(1).

PMID: 37293374 PMC: 10249463. DOI: 10.36922/gtm.288.

The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism.

Mao Y, Zhao K, Li P, Sheng Y Mol Cell Biochem. 2022; 478(5):991-1011.

PMID: 36214893 DOI: 10.1007/s11010-022-04562-6.

Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats.

Chou C, Lin H, Chen J, Fang T PLoS One. 2017; 12(7):e0180712.

PMID: 28700686 PMC: 5507254. DOI: 10.1371/journal.pone.0180712.

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro.

Caminhotto R, Sertie R, Andreotti S, Campaaa A, Lima F Braz J Med Biol Res. 2016; 49(8).

PMID: 27487419 PMC: 4974019. DOI: 10.1590/1414-431X20165409.

Increased Hydration Can Be Associated with Weight Loss.

Thornton S Front Nutr. 2016; 3:18.

PMID: 27376070 PMC: 4901052. DOI: 10.3389/fnut.2016.00018.

References

Massiera F, Ceiler D, Murakami K, Fukamizu A, Gasc J, Quignard-Boulange A . Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001; 15(14):2727-9. DOI: 10.1096/fj.01-0457fje. View

Takahashi N, Li F, Hua K, Deng J, Wang C, Bowers R . Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab. 2007; 6(6):506-12. PMC: 2174204. DOI: 10.1016/j.cmet.2007.10.011. View

Unger R . Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144(12):5159-65. DOI: 10.1210/en.2003-0870. View

Lafontan M . Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol. 2005; 45:119-46. DOI: 10.1146/annurev.pharmtox.45.120403.095843. View

Phillips M, Speakman E, Kimura B . Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 1993; 43(1-2):1-20. DOI: 10.1016/0167-0115(93)90403-u. View

Zanchi A, Dulloo A, Perregaux C, Montani J, Burnier M . Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab. 2007; 293(1):E91-5. DOI: 10.1152/ajpendo.00024.2007. View

Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P . Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 2005; 54(4):991-9. DOI: 10.2337/diabetes.54.4.991. View

Tschop M, Hui D, Horvath T . Diet-induced leptin resistance: the heart of the matter. Endocrinology. 2007; 148(3):921-3. DOI: 10.1210/en.2006-1708. View

Cassis L, English V, Bharadwaj K, Boustany C . Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology. 2003; 145(1):169-74. DOI: 10.1210/en.2003-0767. View

10.

Jones B, Standridge M, Taylor J, Moustaid N . Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol. 1997; 273(1 Pt 2):R236-42. DOI: 10.1152/ajpregu.1997.273.1.R236. View

11.

Staessen J, Li Y, Richart T . Oral renin inhibitors. Lancet. 2006; 368(9545):1449-56. DOI: 10.1016/S0140-6736(06)69442-7. View

12.

Harp J, DIGIROLAMO M . Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J Gerontol A Biol Sci Med Sci. 1995; 50(5):B270-6. DOI: 10.1093/gerona/50a.5.b270. View

13.

Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma A . Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens. 1999; 17(4):555-60. DOI: 10.1097/00004872-199917040-00014. View

14.

Poulsen K, Jorgensen J . An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab. 1974; 39(5):816-25. DOI: 10.1210/jcem-39-5-816. View

15.

Galvez-Prieto B, Bolbrinker J, Stucchi P, De las Heras A, Merino B, Arribas S . Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008; 197(1):55-64. DOI: 10.1677/JOE-07-0284. View

16.

Darimont C, Vassaux G, Ailhaud G, Negrel R . Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology. 1994; 135(5):2030-6. DOI: 10.1210/endo.135.5.7956925. View

17.

Kim S, Soltani-Bejnood M, Quignard-Boulange A, Massiera F, Teboul M, Ailhaud G . The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol. 2007; 2006(5):27012. PMC: 1698261. DOI: 10.1155/JBB/2006/27012. View

18.

Gorzelniak K, Engeli S, Janke J, Luft F, Sharma A . Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002; 20(5):965-73. DOI: 10.1097/00004872-200205000-00032. View

19.

Cassis L, Lynch K, Peach M . Localization of angiotensinogen messenger RNA in rat aorta. Circ Res. 1988; 62(6):1259-62. DOI: 10.1161/01.res.62.6.1259. View

20.

Benson S, Pershadsingh H, Ho C, Chittiboyina A, Desai P, Pravenec M . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43(5):993-1002. DOI: 10.1161/01.HYP.0000123072.34629.57. View